AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28190761 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-DOC (3 cycles of epirubicin, 5-fluorouracil, and cyclophosphamide followed by 3 cycles of docetaxel)
Number of subjects: 3547
Study 28190761 — intervention group
Group type: COMPARATOR
Intervention: DOC-C (6 cycles of docetaxel and cyclophosphamide)
Number of subjects: 3547
Study 28190761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (FEC-DOC and DOC-C)
Number of subjects: 3547
Study 25800686 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV) using a Novalung R100(®) ventilator until the start of weaning.
Number of subjects: 795
Study 25800686 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation.
Number of subjects: 795
Study 25800686 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 795
Study 25800686 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 795
Study 23859929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (10% weight loss goal)
Number of subjects: 118
Study 23859929 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐to‐vigorous aerobic exercise (225 min/week)
Number of subjects: 118
Study 23859929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet+exercise
Number of subjects: 118
Study 23859929 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 118
Study 20667273 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal presentation with no concurrent task
Number of subjects: 0
Study 20667273 — intervention group
Group type: COMPARATOR
Intervention: Peripheral presentation with perceptual load task
Number of subjects: 0
Study 20667273 — intervention group
Group type: COMPARATOR
Intervention: Foveal presentation with concurrent task
Number of subjects: 0
Study 18377636 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment (therapy group) of up to ten treatment sessions focusing on high velocity, low amplitude manipulation of the cervical and thoracic spine, mobilisation, and soft tissue techniques.
Number of subjects: 300
Study 18377636 — intervention group
Group type: COMPARATOR
Intervention: Advice promoting self-management and individual instructions focusing on posture and muscle stretch (advice group).
Number of subjects: 300
Study 16339351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic group (Hyp) with inspired O2 fraction = 14.5%
Number of subjects: 15
Study 16339351 — intervention group
Group type: COMPARATOR
Intervention: Normoxic group (Nor) with inspired O2 fraction = 21%
Number of subjects: 15
Study 16339351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic group (Hyp)
Number of subjects: 15
Study 16339351 — intervention group
Group type: COMPARATOR
Intervention: Normoxic group (Nor)
Number of subjects: 15
Study 15022575 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiclav (amoxicillin + clavulanic acid) administered parenterally i.v. (adults at a dose of 3 x 1.2 gr i.v.; children at a dose of 3 x 30 mg/kg) with early oral switch therapy (adults at a dose of 3 x 625 mg per os; children at a dose of 3 x 25‐50 mg/kg)
Number of subjects: 240
Study 15022575 — intervention group
Group type: COMPARATOR
Intervention: Parenteral regimen without transition to oral dosage form
Number of subjects: 240
Study 11060951 — intervention group
Group type: EXPERIMENTAL
Intervention: Galloy restorative material
Number of subjects: 14
Study 11060951 — intervention group
Group type: COMPARATOR
Intervention: Dispersalloy control material
Number of subjects: 14
Study 8676798 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/day)
Number of subjects: 37
Study 8676798 — intervention group
Group type: COMPARATOR
Intervention: Pyridoxine (70 mg/day)
Number of subjects: 37
Study 1563900 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief group psychotherapy
Number of subjects: 0
Study 1563900 — intervention group
Group type: COMPARATOR
Intervention: No-treatment (control)
Number of subjects: 0
Study 3907298 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 4080
Study 3907298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4080
Study 30801548 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-exposure CNI
Number of subjects: 2026
Study 30801548 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA) with standard-exposure CNI
Number of subjects: 2026
Study 29361967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (15% CHO, 60% fat, 25% protein)
Number of subjects: 20
Study 29361967 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat diet (55% CHO, 20% fat, 25% protein)
Number of subjects: 20
Study 27447365 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,200 repetitions of task-specific upper-limb training
Number of subjects: 85
Study 27447365 — intervention group
Group type: EXPERIMENTAL
Intervention: 9,600 repetitions of task-specific upper-limb training
Number of subjects: 85
Study 27447365 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized maximum repetitions of task-specific upper-limb training
Number of subjects: 85
Study 27447365 — intervention group
Group type: EXPERIMENTAL
Intervention: 6,400 repetitions of task-specific upper-limb training
Number of subjects: 85
Study 24652410 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-driven, depletive fluid-management group
Number of subjects: 304
Study 24652410 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 304
Study 22328739 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS945429 (80 mg)
Number of subjects: 127
Study 22328739 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS945429 (160 mg)
Number of subjects: 127
Study 22328739 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS945429 (320 mg)
Number of subjects: 127
Study 22328739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 21049175 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy (duration: 1 to 7 years)
Number of subjects: 90
Study 21049175 — intervention group
Group type: COMPARATOR
Intervention: Natural evolution of DMD (Scott's study)
Number of subjects: 90
Study 17034006 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (mean dose 119.2 +/- 56.4 mg)
Number of subjects: 58
Study 17034006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 16274152 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate provisional crown with insertion torque of 20 Ncm
Number of subjects: 23
Study 16274152 — intervention group
Group type: COMPARATOR
Intervention: Control group (implants restored after a healing period)
Number of subjects: 23
Study 16274152 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion torque above 32 Ncm
Number of subjects: 23
Study 11898006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush immunotherapy (RIT) with IFA whole body extract (WBE)
Number of subjects: 59
Study 11898006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush immunotherapy (RIT) with IFA WBE
Number of subjects: 59
Study 11898006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no premedication)
Number of subjects: 59
Study 10414941 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 2500
Study 10414941 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 2500
Study 10414941 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific diabetes prevalence
Number of subjects: 2500
Study 10414941 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific IFG prevalence
Number of subjects: 2500
Study 10414941 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations with diabetes and IFG
Number of subjects: 2500
Study 10414941 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison with Americans
Number of subjects: 2500
Study 7583862 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-24 (anhydrous extended-release capsules) plus inhaled beta 2-agonist
Number of subjects: 61
Study 7583862 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus inhaled beta 2-agonist
Number of subjects: 61
Study 1965904 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU plus VM-26 plus 5-FU
Number of subjects: 173
Study 1965904 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU plus VM-26
Number of subjects: 173
Study 1965904 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU alone
Number of subjects: 173
Study 347106 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole as an immune adjuvant in addition to standard therapy
Number of subjects: 37
Study 347106 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 37
Study 31734121 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g × 2 whey-enriched protein supplementation
Number of subjects: 218
Study 31734121 — intervention group
Group type: EXPERIMENTAL
Intervention: isocaloric placebo
Number of subjects: 218
Study 31734121 — intervention group
Group type: COMPARATOR
Intervention: Control with no supplementation
Number of subjects: 218
Study 31734121 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups (including whey and isocaloric)
Number of subjects: 218
Study 31083000 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anaesthesia combined with desflurane anaesthesia
Number of subjects: 62
Study 31083000 — intervention group
Group type: COMPARATOR
Intervention: Desflurane balanced anaesthesia
Number of subjects: 62
Study 29084318 — intervention group
Group type: COMPARATOR
Intervention: LOW SFM+
Number of subjects: 172
Study 29084318 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH SFM+
Number of subjects: 172
Study 25427288 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Paravertebral Blockade (PVB) with ropivacaine 0.5%
Number of subjects: 83
Study 25427288 — intervention group
Group type: COMPARATOR
Intervention: Incisional Local Anesthetic Administration (port infiltration) with ropivacaine 0.5%
Number of subjects: 83
Study 23335039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest α-tocopherol quartile
Number of subjects: 1046
Study 23335039 — intervention group
Group type: COMPARATOR
Intervention: α-tocopherol
Number of subjects: 1046
Study 22336064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1.0% combined with Proparacaine Hydrochloride 0.5% (Pro+Cyc group)
Number of subjects: 71
Study 22336064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1.0% (NS+Cyc group)
Number of subjects: 71
Study 22336064 — intervention group
Group type: COMPARATOR
Intervention: Atropine 1.0% (used one week later for three days)
Number of subjects: 71
Study 22336064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1.0%
Number of subjects: 71
Study 19183462 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing training for primary care nurses
Number of subjects: 700
Study 19183462 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 700
Study 17168427 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) as a primary endpoint
Number of subjects: 405
Study 17168427 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality score of trials
Number of subjects: 405
Study 17168427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with publication year
Number of subjects: 405
Study 17168427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with type of journal
Number of subjects: 405
Study 17168427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with presence of biostatistician
Number of subjects: 405
Study 17168427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with number of participating institutions
Number of subjects: 405
Study 12739685 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal ligament injection (PDLi) with a computerized device (Wand)
Number of subjects: 98
Study 12739685 — intervention group
Group type: COMPARATOR
Intervention: Conventional buccal infiltration
Number of subjects: 98
Study 12739685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (PDLi and conventional infiltration)
Number of subjects: 98
Study 11142541 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy for Children (SET-C)
Number of subjects: 67
Study 11142541 — intervention group
Group type: COMPARATOR
Intervention: Testbusters (active, but nonspecific intervention)
Number of subjects: 67
Study 11142541 — intervention group
Group type: EXPERIMENTAL
Intervention: SET-C
Number of subjects: 67
Study 9589728 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal approach phacoemulsification combined with separate superior trabeculectomy (Group B)
Number of subjects: 50
Study 9589728 — intervention group
Group type: COMPARATOR
Intervention: Standard superior phacotrabeculectomy (Group A)
Number of subjects: 50
Study 9589728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 50
Study 8463913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 176
Study 8463913 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 176
Study 4061524 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg of calcium L-aspartate daily)
Number of subjects: 22
Study 4061524 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented group
Number of subjects: 22
Study 4061524 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 22
Study 30529244 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure)
Number of subjects: 81
Study 30529244 — intervention group
Group type: COMPARATOR
Intervention: RP (Relapse Prevention)
Number of subjects: 81
Study 29878826 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 126
Study 29878826 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive rehabilitation (CR)
Number of subjects: 126
Study 29878826 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-directed manualized CR
Number of subjects: 126
Study 29878826 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-directed CR integrated with cognitive-behavioral psychotherapy
Number of subjects: 126
Study 29878826 — intervention group
Group type: EXPERIMENTAL
Intervention: Team treatment milieu
Number of subjects: 126
Study 29878826 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid depression
Number of subjects: 126
Study 26475930 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous insert regimens
Number of subjects: 180
Study 26475930 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous insert groups
Number of subjects: 180
Study 26475930 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous vector regimens
Number of subjects: 180
Study 24839984 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica gel fibre (SGF) in addition to standard treatment
Number of subjects: 120
Study 24839984 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment (S-o-C) alone
Number of subjects: 120
Study 23232109 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol care (3 weeks)
Number of subjects: 193
Study 23232109 — intervention group
Group type: COMPARATOR
Intervention: Usual care (3 weeks)
Number of subjects: 193
Study 20162747 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 5
Study 20162747 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 5
Study 17285423 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO(4) 40 mg.kg(‐1)
Number of subjects: 22
Study 17285423 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 22
Study 15642806 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision therapy/orthoptics
Number of subjects: 47
Study 15642806 — intervention group
Group type: COMPARATOR
Intervention: Pencil push-ups
Number of subjects: 47
Study 15642806 — intervention group
Group type: COMPARATOR
Intervention: Placebo vision therapy/orthoptics
Number of subjects: 47
Study 12119223 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (3 mcg/kg intravenous daily for 5 days)
Number of subjects: 18
Study 12119223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10466241 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 10466241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (letrozole, anastrazole)
Number of subjects: 0
Study 10466241 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH agonists
Number of subjects: 0
Study 10466241 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimens (CMF or CAF)
Number of subjects: 0
Study 10466241 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes (paclitaxel and docetaxel)
Number of subjects: 0
Study 7473906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg via enteral route
Number of subjects: 18
Study 7473906 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 100 mg via intravenous (IV) route
Number of subjects: 18
Study 2258807 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nonsteroidal anti-inflammatory agent (0.03% flurbiprofen)
Number of subjects: 0
Study 2258807 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid (1% prednisolone acetate)
Number of subjects: 0
Study 7029684 — intervention group
Group type: EXPERIMENTAL
Intervention: Razoxane (125 mg twice daily for 5 consecutive days every week indefinitely)
Number of subjects: 162
Study 7029684 — intervention group
Group type: COMPARATOR
Intervention: Control (usual clinical care without razoxane)
Number of subjects: 162
Study 31532235 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training exergame
Number of subjects: 22
Study 31666825 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 456
Study 31666825 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 456
Study 28045551 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-literacy asthma action plan
Number of subjects: 217
Study 28045551 — intervention group
Group type: COMPARATOR
Intervention: Standard asthma action plan
Number of subjects: 217
Study 27140802 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate-tablet regimen (EVG 150mg + COBI 150mg + FTC/TDF 200mg/300mg)
Number of subjects: 24
Study 27140802 — intervention group
Group type: COMPARATOR
Intervention: Single-tablet regimen (EVG/COBI/FTC/TDF)
Number of subjects: 24
Study 27140802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 24
Study 23632659 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 3397
Study 23632659 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 3397
Study 23632659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study 23632659 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA/CE treatment
Number of subjects: 3397
Study 23632659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot flush score reduction at week 12
Number of subjects: 3397
Study 21558036 — intervention group
Group type: EXPERIMENTAL
Intervention: CT fluoroscopy guidance
Number of subjects: 116
Study 21558036 — intervention group
Group type: COMPARATOR
Intervention: C-arm fluoroscopy guidance
Number of subjects: 116
Study 19475630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg oral mecamylamine
Number of subjects: 15
Study 19475630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg oral mecamylamine
Number of subjects: 15
Study 19475630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg oral mecamylamine
Number of subjects: 15
Study 19475630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19025429 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day with prasugrel (60 mg loading dose followed by 10 mg/day)
Number of subjects: 69
Study 19025429 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day with clopidogrel (300 mg loading dose followed by 75 mg/day)
Number of subjects: 69
Study 19025429 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day with prasugrel or clopidogrel
Number of subjects: 69
Study 19025429 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/day
Number of subjects: 69
Study 16557033 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma samples from improvers with declining cytokine levels over time
Number of subjects: 3
Study 16557033 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma samples from nonimprovers with sustained elevation in cytokine levels over time
Number of subjects: 3
Study 16557033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung tissues of patients with severe ARDS
Number of subjects: 3
Study 12122218 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded vision during the first movement (Experiment 1)
Number of subjects: 0
Study 12122218 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded vision during the second movement (Experiment 2)
Number of subjects: 0
Study 12122218 — intervention group
Group type: EXPERIMENTAL
Intervention: One-target advantage when the second movement was in the same direction as the first
Number of subjects: 0
Study 12122218 — intervention group
Group type: EXPERIMENTAL
Intervention: One-target advantage when the second movement was reversed with respect to the home button
Number of subjects: 0
Study 10432470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10432470 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methylphenidate (0.28 mg/kg)
Number of subjects: 20
Study 10432470 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylphenidate (0.56 mg/kg)
Number of subjects: 20
Study 10432470 — intervention group
Group type: COMPARATOR
Intervention: Baseline (off drug)
Number of subjects: 20
Study 8853523 — intervention group
Group type: EXPERIMENTAL
Intervention: New anti-cancer agents in phase II studies
Number of subjects: 0
Study 8853523 — intervention group
Group type: COMPARATOR
Intervention: New anti-cancer agents in phase III studies
Number of subjects: 0